IL37 and myeloid sarcoma: We observed a significantly augmented proportion of samples with dosable circulating IL37 in MS patients treated with high potency DMTs compared to those untreated (36.36% vs. 0%; p = 0.0007, by chi square test with Yates’ correction) and compared to patients treated with platform therapy (36.36% vs. 0%; p = 0.0001, by chi square test with Yates’ correction).